Skip to main content

Table 1 Clinical and pathological characteristics of breast cancer cases

From: Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression

Parameter

Patients

GAL3ST1

IHC

(N = 232)

%

IHC negative

IHC positive

p value (chi-squarea or Fisher exact testb)

Age

 ≤ 50 years

56

24.14

25

31

0.0904b

 > 50 years

176

75.86

102

74

Tumour grade

 G1

67

28.88

30

38

0.0215 b

 G2

96

41.38

53

42

 G3

55

23.71

38

17

 No data

14

6.03

  

Tumour size

 pT1

119

51.29

66

53

0.8706b

 pT2

75

32.33

45

31

 pT3

4

1.72

2

2

 pT4

22

9.48

11

11

 

14

6.03

  

Lymph nodes

 pN0

87

37.50

53

34

0.4386b

 pN1–pN3

67

28.88

46

30

 pNx

 

0.00

  

 No data

12

5.17

  

Stage

 I

53

22.84

33

20

0.6406a

 II

60

25.86

35

25

 III

41

17.67

24

17

 IV

1

0.43

0

1

 No data

78

33.62

  

Oestrogen receptor

 Negative

52

22.41

36

16

0.0203 b

 Positive

167

71.98

85

82

 No data

13

5.60

  

Progesterone receptor

 Negative

69

29.74

40

28

0.4503b

 Positive

150

64.66

80

70

 No data

13

5.60

  

HER2

 Negative

188

81.03

97

90

0.0894b

 Positive

34

14.66

23

11

 No data

10

4.31

  

Molecular tumour types

 Triple negative

18

7.6

11

7

0.5492b

 Other types

199

85.78

107

92

 No data

10

4.31

  

Chemotherapy

 Negative

13

5.60

8

5

0.7764b

 Positive

219

94.4

119

100

Hormonal therapy

 Negative

32

13.79

20

12

0.3398b

 Positive

198

85.34

103

95

 No data

2

0.8

  
  1. Bold values (p < 0.05) are statistically significant
  2. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, Gal3ST1 galactosylceramide sulfotransferase